脑脊液ctDNA及其他生物标志物在原发中枢神经系统淋巴瘤中的研究进展

Research progress of cerebrospinal fluid ctDNA and other biomarkers in primary central nervous system lymphoma

原发中枢神经系统淋巴瘤(PCNSL)是一种罕见的原发于中枢神经系统(CNS)的非霍奇金淋巴瘤,病理类型主要为弥漫性大B细胞淋巴瘤(DLBCL),具有高侵袭性、高复发率、高病死率等特点,且发病率逐年升高。目前在PCNSL的早期检测和筛查、疗效评估、预后监测等方面尚缺乏有效的检测手段。近年来不少国内外研究显示,循环肿瘤DNA(ctDNA)在肿瘤辅助诊断、分子分型、治疗监测及疗效评估等方面具有广泛的应用价值。血浆ctDNA检测指导非小细胞肺癌临床用药已被指南推荐,血浆ctDNA在系统性DLBCL中也有不少研究,但脑脊液(CSF)ctDNA在PCNSL中报道较少。文章就PCNSL患者CSF中ctDNA及其他潜在生物标志物的研究进展作一综述。

Primary central nervous system lymphoma(PCNSL) is a rare type of non Hodgkin’s lymphoma originating from the central nervous system(CNS). The pathological type is mainly diffuse large B-cell lymphoma(DLBCL), which is characterized by high invasion, high recurrence rate, high mortality, and the incidence rate is increasing year by year. At present, there is still a lack of effective detection means in the early detection and screening of PCNSL, efficacy evaluation, prognosis monitoring, etc. In recent years, many studies at home and abroad have shown that circulating tumor DNA(ctDNA) has extensive application value in tumor auxiliary diagnosis, molecular typing, therapeutic monitoring and efficacy evaluation. Plasma ctDNA detection has been recommended by the guidelines to guide the clinical medication of non-small cell lung cancer. There are also many studies on plasma ctDNA in systematic DLBCL, but few reports on cerebrospinal fluid(CSF) ctDNA in PCNSL. This article reviews the research progress of ctDNA and other potential biomarkers in CSF of PCNSL patients.